REGENXBIO, Inc. (RGNX)
5.65
-0.07
(-1.22%)
USD |
NASDAQ |
May 18, 16:00
5.69
+0.04
(+0.71%)
After-Hours: 20:00
REGENXBIO Research and Development Expense (Quarterly) : 53.48M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 153.96M |
| Ocugen, Inc. | 11.26M |
| Replimune Group, Inc. | 52.87M |
| AbbVie, Inc. | 2.472B |
| Krystal Biotech, Inc. | 13.81M |